How sad that the Daily News chose to take aim at a court decision that might have significantly helped the plight of animals, who are the victims of our greed, cruelty, neglect and ...

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...

Last week, readers were most interested in a story about Fujirebio buying all the shares of IVD and life science material firm Plasma Services Group.

H.U. Group Holdings Inc. and its subsidiary Fujirebio Holdings, Inc., have announced that Fujirebio Diagnostics, Inc. has acquired Plasma Services Group, Inc. (PSG), a ...

Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to ...

About Fujirebio Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value.

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

Fujirebio, a leading innovator in in-vitro diagnostics, announced a collaboration with Stanford Medicine to advance research and innovation in the field of infectious disease testing. This ...